Compare the reduction in Framingham's predicted 10-year risk of a coronary event (6) in patients with hypertension and at least three other cardiovascular risk factors (including diabetic patients) seen in private practice and randomized to either Caduet or usual care.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
1,442
% reduction in Framingham's predicted 10-year risk of a coronary event between V1 and V3 in the Caduet group compared to the usual care group (6) (including diabetic patients)
1. % patients changing risk category between V1 and V3 2. % reduction in Framingham's predicted 10-year risk of a coronary event (8) excluding diabetic patients 3. Clinical and biological safety during treatment period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
Abbeville, France
Pfizer Investigational Site
Aire-sur-la-Lys, France
Pfizer Investigational Site
Aix-les-Bains, France
Pfizer Investigational Site
Alençon, France
Pfizer Investigational Site
Allaire, France
Pfizer Investigational Site
Amboise, France
Pfizer Investigational Site
Amiens, France
Pfizer Investigational Site
Amiens, France
Pfizer Investigational Site
Amiens, France
Pfizer Investigational Site
Andrézieux-Bouthéon, France
...and 374 more locations